Affiliation:
1. University of Campinas (UNICAMP)
2. Universidade Estadual de Campinas - UNICAMP
Abstract
Abstract
Objective
To evaluate gene expression associated with unfavorable vaginal bleeding in users of the Etonogestrel (ENG) contraceptive implant.
Materials and Methods
prospective study involving 100 women who intended to use the ENG implant. Exclusion criteria included abnormal uterine bleeding, inability to attend a 1-year follow-up, and implant removal for reasons unrelated to vaginal bleeding or loss of follow-up. We obtained endometrial biopsies before implant placement and assessed the expression of 20 selected genes. Users maintained a uterine bleeding diary for 12 months post-implant placement. For statistical analysis, we categorized women into those with or without favorable vaginal bleeding at 3 and 12 months.
Results
Women with lower CXCL1 expression had a 6.8-fold increased risk of unfavorable vaginal bleeding at 3 months (OR 6.8, 95% CI 2.21–20.79, p < 0.001), while those with higher BCL6 and BMP6 expression had 6- and 5.1-fold increased risks, respectively. By the 12-month follow-up, women with lower CXCL1 expression had a 5.37-fold increased risk of unfavorable vaginal bleeding (OR 5.37, 95% CI 1.63–17.73, p = 0.006). Women with CXCL1 expression < 0.0675, BCL6 > 0.65, and BMP6 > 3.4 had a higher likelihood of experiencing unfavorable vaginal bleeding at 3 months, and CXCL1 < 0.158 at 12 months.
Conclusion
Users of ENG contraceptive implants with elevated BCL6 and BMP6 expression exhibited a higher risk of breakthrough bleeding at the 3-month follow-up. Conversely, reduced CXCL1 expression was associated with an elevated risk of bleeding at both the 3 and 12-month follow-ups.
Publisher
Research Square Platform LLC
Reference39 articles.
1. - Curtis KM, Ph.D., Peipert JF. Long-Acting Reversible Contraception N Engl J Med 2017; 376:461–468.
2. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-random- ized matched copper-intrauterine device controls;- Bahamondes L;Hum Reprod,2015
3. Management of bothersome bleeding associated with progestin-based long-acting reversible contraception: a review;Goldthwaite LM;Curr Opin Obstet Gynecol,2020
4. -Hickey M, Fraser IS. The structure of endometrial microvessels. Human reproduction. 2000; 15 Suppl 3:57–66. PMID: 11041222. 5-. Hickey M, Krikun G, Kodaman P, Schatz F, Carati C, Lockwood CJ. Long-term progestin-only contraceptives result in reduced endometrial blood flow and oxidative stress. The Journal of clinical endocrinology and metabolism. 2006; 91(9):3633–8. doi: 10.1210/jc.2006-0724 PMID: 16757524.
5. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels;- Shaaban MM;Fertil Steril,1993